SynthesisAnti-cancer agents in medicinal chemistry2026
Comparative Prognosis of HER2-Low versus HER2-Negative Breast Cancer: A Meta-Analysis.
Synthesis in Anti-cancer agents in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWith the emergence of new antibody-drug conjugates (ADCs), low human epidermal growth factor receptor (HER2) expression may become a novel treatment target. However, despite the clinical trials of new ADCs, strong evidence to prove the practical significance of HER2-low breast cancer (BC) prognosis remains unavailable.
methodsThis systematic meta-analysis was undertaken to compare the prognostic value of the survival outcomes of patients with HER2-negative and HER2-low BC. For this, the Cochrane Library and PubMed were searched, and 23 eligible retrospective or prospective studies reporting information related to disease-free survival (DFS), overall survival (OS), and pathological complete response (PCR) rates of patients with HER2- negative and HER2-low BC were included. For both subgroups, the data were pooled using a random-effects model, with hazard ratios (HRs) for OS and DFS and odds ratios (ORs) for PCR, along with their 95% confidence intervals (CIs). OS was the primary endpoint, whereas DFS and PCR rates were the secondary endpoints.
resultsWe analyzed the 23 studies, which enrolled 781,941 patients with HER2-low BC. OS (HR = 0.82, 95% CI: 0.73-0.92, P = 0.001) significantly improved in patients with HER2-low BC compared with those with HER2-negative BC. However, DFS (HR = 0.87, 95% CI: 0.67-1.12, P = 0.28) did not significantly improve. Furthermore, the PCR rate was lower in patients with HER2-low BC than in patients with HER2-negative BC (OR = 0.88, 95% CI: 0.83-0.93, P < 0.001).
conclusionCompared with the HER2-negative status, OS is significantly increased, and PCR is significantly decreased in the HER2-low status. However, DFS is not significantly increased.
Indexed as
Identifiers
41833026What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.